Bluebird bio Inc (BLUE)

1.2200 +0.0900 (+7.96%)
Close USD Disclaimer
1.1900 -0.0300 (-2.4590%)

Bluebird bio Inc Company Profile

Sector
Healthcare
Employees
518
Equity Type
ORD
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
Contact Information
Address
Cambridge,02142 United States
Phone
339 499 9300
Fax
-
Top Executives
Name
Age
Since
Title
Mitchell H. Finer 64 2010 Member of Scientific Advisory Board
Najoh Tita-Reid 0 2021 Director
Andrew M. Scharenberg 0 0000 Member of Scientific Advisory Board
Philip R. Reilly 75 2010 Member of Scientific Advisory Board
Malcolm K. Brenner 71 2011 Member of Scientific Advisory Board
Christof von Kalle 0 2011 Member of Scientific Advisory Board
R. Keith Humphries 0 2011 Member of Scientific Advisory Board
Mark L. Vachon 64 2014 Independent Chairman
Stephen P. Goff 71 2011 Member of Scientific Advisory Board
Philippe Leboulch 0 0000 Co-Chair of Scientific Advisory Board
John O. Agwunobi 58 2017 Independent Director
Andrew Obenshain 48 2016 President, CEO & Director
Richard A. Paulson 56 2023 Independent Director
Elisabeth Leiderman 46 2021 Independent Director
Charlotte Jones-Burton 49 2022 Independent Director
Michael Cloonan 53 2024 Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles